Halozyme Therapeutics (HALO) Misses Q3 EPS by 3c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $110.19 -0.51%
EPS Growth %: +30.2%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +30.2%
Financial Fact:
Total operating expenses: 54.6M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.19), $0.03 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $24.01 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Lynx Equity sees Micron and SanDisk breakout as volatility normalizes
- JPMorgan Starts Bechtle AG (BC8:GR) (BECTY) at Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
